Cannabis education course is now mandatory in Ontario
The clarity of how cannabis should be used is less black-and-white than many prescription drugs.
Patients in Jersey could be inline to participate in cannabis trials.
‘Jersey is world-renowned for having first-class agricultural standards and best practices,’
[Medical cannabis: the opportunity versus the temptation]
The cannabis plant has been known to humanity for centuries as a remedy for pain, diarrhea, and inflammation. Current research has shown cannabis to be a useful remedy for many diseases, including multiple sclerosis, dystonia, and chronic pain. Cannabinoids are used to improve food intake in anorexia of AIDS patients and to prevent vomiting due to cancer chemotherapy. We must not be blind to the opportunity offered to us by medical cannabis just because it is an illicit drug, nor should we be temped by the quick response of patients to the central effect of cannabis. More research is warranted to explore the full potential of cannabis as medicine.
Tilray® Announces Support of Two New Clinical Research Studies in Australia and Canada
Murdoch Children’s Research Institute in Australia & McGill University Health Centre’s Division of Infectious Diseases and Chronic Viral Illness to benefit from Tilray’s support
Can medicinal cannabis treat the tics in Tourette syndrome?
“This clinical trial could have a major impact and greatly improve the lives of those living with Tourette syndrome.”
Cannabis-based medicine to be tested in Alzheimer’s
Sativex® for the Treatment of AgitatioN in Dementia (STAND trial)
UK medical cannabis trials are to be backed by Canopy Growth Corp
All eyes are focused on the U.K. right now to see this program move forward,”
Charity funding to research cannabinoid medicine for EB suffers
The research will investigate if additional treatment with this sublingual oil can improve the quality of life of adults with EB suffering from pain and/or itch
Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs
Background: Medical cannabis has been available in the State of Minnesota since July 2015 through the Minnesota Medical CannabisProgram (MMCP). Objectives: Our study aimed to delineate oncology providers’ views on medical cannabis, identify barriers to patient enrollment, and assess clinicians’ interest in a clinical trial of medical cannabis in patients with stage IV cancer. This study illustrates a clear need to give clinicians both data and education to guide their discussions about the benefits, risks, and cost considerations of using medical cannabis for cancer-related symptoms.
Becoming a Medical cannabis patient in Queensland may hopefully get easier.
The change would significantly streamline the prescription process